Drug maker Mycenax Biotech Inc (永昕生技) yesterday said revenue would double this year from last year, as the company gears up to develop and manufacture drugs for clients on a contract basis.
The Miaoli County-based company also expects sales for next year to double from this year, Mycenax president Karen Wen (溫國蘭) said at an investors’ conference in Taipei.
Mycenax reported revenue of NT$54.94 million (US$1.86 million) for the first 11 months of the year, up 90.63 percent from NT$28.82 million a year ago, but the company will remain in red this year after posting losses of NT$78.92 million, or NT$0.85 per share, during the first three quarters.
Losses shrank from the year-earlier level of NT$91.08 million, or NT$1.58 per share, but Wen said: “It is still not likely for us to swing to the black next year, but we will try to keep our cash flow positive.”
To finance the development of new drugs and bolster its working capital, Mycenax is planning to issue 12.98 million new shares to raise NT$1.4 billion. The company is scheduled to shift to trade its shares on the main board from the Emerging Stock Market (興櫃市場) on Dec. 25.
“By the end of 2020, we will launch two to four biosimilar products for curing autoimmune diseases, co-develop two biosimilars for curing cancer and send two new protein drugs into phase-one clinical trials in Taiwan,” Wen said.
The company currently has no product on the market.
Mycenax’s TuNEX, which was co-developed with drug maker TSH Biopharm Corp (東生華) to treat rheumatoid arthritis, is expected to pass all clinical trials in 2015, while its neutropenia drug GranNEX could enter clinical trials by the end of this year, the company said.
The company has a bioreactor with a capacity of 500 liters to make protein drugs in the Hsinchu Science Park (新竹科學園區). Mycenax is constructing a new bioreactor of 2,000 liters, which will be the largest in Taiwan, the company said.
Mycenax will start the trial run of its 2,000-liter reactor in January and it expects the reactor to be operational in the second half of next year.
The company said the utilization rate of its new bioreactor will be at 80 percent in 2015.
Wen said the company can extract 2g of protein drug for every liter, and it can extract 32g of protein drug per liter if manufacturing in a small scale.
During the January-to-September period, the company spent NT$70.92 million on research and development, down 16.22 percent from NT$84.65 million a year ago, according to the company’s filing to the Taiwan Stock Exchange.
Mycenax was established in 2001, focusing on developing and manufacturing biologics, or products made from living cells, blood factors and genetically engineered proteins.
The company has a paid-in capital of NT$973 million, with major shareholders including Center Laboratories Inc (晟德), Nien Hsing Textile Co (年興紡織), Taiwan Global BioFund (上智生技創投) and the National Development Fund (國發基金) of the Executive Yuan.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”